File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Inhaled fluticasone in bronchiectasis: A 12 month study
  • Basic View
  • Metadata View
  • XML View
TitleInhaled fluticasone in bronchiectasis: A 12 month study
 
AuthorsTsang, KW1
Tan, KC1
Ho, PL1
Ooi, GC1
Ho, JC1
Mak, J1
Tipoe, GL1
Ko, C1
Yan, C1
Lam, WK1
ChanYeung, M1
 
Issue Date2005
 
PublisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/
 
CitationThorax, 2005, v. 60 n. 3, p. 239-243 [How to Cite?]
DOI: http://dx.doi.org/10.1136/thx.2002.003236
 
AbstractBackground: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μ9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ≤2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.
 
ISSN0040-6376
2012 Impact Factor: 8.376
2012 SCImago Journal Rankings: 2.742
 
DOIhttp://dx.doi.org/10.1136/thx.2002.003236
 
PubMed Central IDPMC1747352
 
ISI Accession Number IDWOS:000227470700016
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTsang, KW
 
dc.contributor.authorTan, KC
 
dc.contributor.authorHo, PL
 
dc.contributor.authorOoi, GC
 
dc.contributor.authorHo, JC
 
dc.contributor.authorMak, J
 
dc.contributor.authorTipoe, GL
 
dc.contributor.authorKo, C
 
dc.contributor.authorYan, C
 
dc.contributor.authorLam, WK
 
dc.contributor.authorChanYeung, M
 
dc.date.accessioned2007-01-08T02:27:02Z
 
dc.date.available2007-01-08T02:27:02Z
 
dc.date.issued2005
 
dc.description.abstractBackground: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μ9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ≤2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.
 
dc.description.naturepublished_or_final_version
 
dc.format.extent101963 bytes
 
dc.format.extent25088 bytes
 
dc.format.extent618083 bytes
 
dc.format.extent4522 bytes
 
dc.format.mimetypeapplication/pdf
 
dc.format.mimetypeapplication/msword
 
dc.format.mimetypeapplication/pdf
 
dc.format.mimetypetext/plain
 
dc.identifier.citationThorax, 2005, v. 60 n. 3, p. 239-243 [How to Cite?]
DOI: http://dx.doi.org/10.1136/thx.2002.003236
 
dc.identifier.doihttp://dx.doi.org/10.1136/thx.2002.003236
 
dc.identifier.epage243
 
dc.identifier.hkuros117978
 
dc.identifier.isiWOS:000227470700016
 
dc.identifier.issn0040-6376
2012 Impact Factor: 8.376
2012 SCImago Journal Rankings: 2.742
 
dc.identifier.issue3
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC1747352
 
dc.identifier.pmid15741443
 
dc.identifier.scopuseid_2-s2.0-20144377363
 
dc.identifier.spage239
 
dc.identifier.urihttp://hdl.handle.net/10722/42019
 
dc.identifier.volume60
 
dc.languageeng
 
dc.publisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofThorax
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThorax. Copyright © B M J Publishing Group.
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshAdministration, inhalation
 
dc.subject.meshAndrostadienes - administration & dosage
 
dc.subject.meshBronchiectasis - drug therapy
 
dc.subject.meshForced expiratory volume - physiology
 
dc.subject.meshVital capacity
 
dc.titleInhaled fluticasone in bronchiectasis: A 12 month study
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tsang, KW</contributor.author>
<contributor.author>Tan, KC</contributor.author>
<contributor.author>Ho, PL</contributor.author>
<contributor.author>Ooi, GC</contributor.author>
<contributor.author>Ho, JC</contributor.author>
<contributor.author>Mak, J</contributor.author>
<contributor.author>Tipoe, GL</contributor.author>
<contributor.author>Ko, C</contributor.author>
<contributor.author>Yan, C</contributor.author>
<contributor.author>Lam, WK</contributor.author>
<contributor.author>ChanYeung, M</contributor.author>
<date.accessioned>2007-01-08T02:27:02Z</date.accessioned>
<date.available>2007-01-08T02:27:02Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Thorax, 2005, v. 60 n. 3, p. 239-243</identifier.citation>
<identifier.issn>0040-6376</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/42019</identifier.uri>
<description.abstract>Background: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation. Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 &#956;9 twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion. Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01 ) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume &lt;30 ml (p = 0.04), exacerbation frequency &#8804;2/year (p = 0.04), and sputum purulence score &gt;5 (p = 0.03). Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.</description.abstract>
<format.extent>101963 bytes</format.extent>
<format.extent>25088 bytes</format.extent>
<format.extent>618083 bytes</format.extent>
<format.extent>4522 bytes</format.extent>
<format.mimetype>application/pdf</format.mimetype>
<format.mimetype>application/msword</format.mimetype>
<format.mimetype>application/pdf</format.mimetype>
<format.mimetype>text/plain</format.mimetype>
<language>eng</language>
<publisher>B M J Publishing Group. The Journal&apos;s web site is located at http://thorax.bmjjournals.com/</publisher>
<relation.ispartof>Thorax</relation.ispartof>
<rights>Thorax. Copyright &#169; B M J Publishing Group.</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Administration, inhalation</subject.mesh>
<subject.mesh>Androstadienes - administration &amp; dosage</subject.mesh>
<subject.mesh>Bronchiectasis - drug therapy</subject.mesh>
<subject.mesh>Forced expiratory volume - physiology</subject.mesh>
<subject.mesh>Vital capacity</subject.mesh>
<title>Inhaled fluticasone in bronchiectasis: A 12 month study</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0040-6376&amp;volume=60&amp;issue=3&amp;spage=239&amp;epage=243&amp;date=2005&amp;atitle=Inhaled+fluticasone+in+bronchiectasis:+a+12+month+study</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1136/thx.2002.003236</identifier.doi>
<identifier.pmid>15741443</identifier.pmid>
<identifier.pmcid>PMC1747352</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-20144377363</identifier.scopus>
<identifier.hkuros>117978</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-20144377363&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>60</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>239</identifier.spage>
<identifier.epage>243</identifier.epage>
<identifier.isi>WOS:000227470700016</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/42019/1/117978.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong